Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Huda Salman
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03829540CT.gov CD4CAR for CD4+ Leukemia and Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd4car (this asset) | Huda Salman | P1 | CC · 43 |
| Cyclophosphamide | Xinqiao Hospital of Chongqing | P2 | B |
| (+)-Vincristine | Children's Oncology Group | P2 | B |
| Cytarabine | Children's Oncology Group | P2 | B |
| Pegaspargase | Children's Oncology Group | P2 | B |
| Methotrexate | Children's Oncology Group | P2 | B |
| A-Dmdt390-Bisfv(Ucht1) | Virogen Biotechnology Inc. | P2 | CCC |
| Clofarabine | St. Jude Children's Research Hospital | P2 | CCC |
| Mercaptopurine Anhydrous | St. Jude Children's Research Hospital | P2 | CCC |
+20 more in the T-Cell Leukemia cohort
Other indications for cd4car
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 41 |
| Acute Myeloid Leukemia | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd4car in T-Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd4car-t-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →